Close Menu

stock split

After the split, the Norwegian firm had about 27 million shares of common stock outstanding.

MDRNA, now known as Marina Biotech, plans a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the acquisition of Cequent.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.